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ABSTRACT
Background Centralisation of healthcare, especially for
advanced cancer surgery, has been a matter of debate.
Clear short-term mortality beneﬁts have been described
for oesophageal cancer surgery conducted at high-
volume hospitals and by high-volume surgeons.
Objective To clarify the association between hospital
volume, surgeon volume and hospital type in relation to
long-term survival after oesophagectomy for cancer, by a
meta-analysis.
Design The systematic literature search included
PubMed, Web of Science, Cochrane library, EMBASE and
Science Citation Index, for the period 1990–2013.
Eligible articles were those which reported survival (time
to death) as HRs after oesophagectomy for cancer by
hospital volume, surgeon volume or hospital type. Fully
adjusted HRs for the longest follow-up were the main
outcomes. Results were pooled by a meta-analysis, and
reported as HRs and 95% CIs.
Results Sixteen studies from seven countries met the
inclusion criteria. These studies reported hospital volume
(N=13), surgeon volume (N=4) or hospital type (N=4).
A survival beneﬁt was found for high-volume hospitals
(HR=0.82, 95% CI 0.75 to 0.90), and possibly also, for
high-volume surgeons (HR=0.87, 95% CI 0.74 to 1.02)
compared with their low-volume counterparts. No
association with survival remained for hospital volume
after adjustment for surgeon volume (HR=1.01, 95% CI
0.97 to 1.06; N=2), while a survival beneﬁt was found
in favour of high-volume surgeons after adjustment for
hospital volume (HR=0.91, 95% CI 0.85 to 0.98; N=2).
Conclusions This meta-analysis demonstrated better
long-term survival (even after excluding early deaths)
after oesophagectomy with high-volume surgery, and
surgeon volume might be more important than hospital
volume. These ﬁndings support centralisation with fewer
surgeons working at large centres.
INTRODUCTION
Centralisation of complex cancer surgery is a topic
of debate in several countries. Such centralisation
can improve care by collating multidisciplinary
expertise and experience, as well as specialised
equipment, within centres of excellence, and will
affect the healthcare budget. Treating more patients
should improve the skills of the medical team, and
adapting speciﬁc treatment procedures should
facilitate and improve patient-tailored care.
However, the beneﬁt of such centralisation should
be weighed up against the potential disadvantages
for patients— for example, long travel times and
social isolation.1 Oesophageal cancer surgery is one
of the most complex surgical procedures, entailing
a substantial risk of severe postoperative complica-
tions, and a convincing beneﬁt of centralisation has
been shown for short-term mortality (in-hospital
and 30-day postoperatively) for this operation.2–7
However, the existing data describing oesophageal
cancer surgery volume in relation to long-term sur-
vival are limited, and the results from individual
studies are contradictory.7 Moreover, the inﬂuence
of tumour stage has not always been taken into
Signiﬁcance of this study
What is already known about this subject?
▸ Oesophageal cancer has a very poor prognosis,
with a 5-year survival of only 30% after
complete oesophageal cancer resection
(oesophagectomy).
▸ Oesophagectomy is one of the most complex
surgical procedures, entailing a substantial risk
of severe postoperative complications.
▸ Short-term mortality (in-hospital and 30-day
postoperatively) has been shown to be lower if
operations are carried out in high-volume
hospitals and/or by high-volume surgeons. Yet,
95% of all patients survive the ﬁrst 30 days
after surgery.
▸ Based on these differences in short-term
mortality, centralisation of oesophagectomy
within centres of excellence has been
recommended and adopted in many countries.
What are the new ﬁndings?
▸ This meta-analysis demonstrated a better
long-term survival after oesophagectomy with
high-volume surgery.
▸ Surgeon volume seems to be more important
than hospital volume.
How might it impact on clinical practice in
the foreseeable future?
▸ Differences in long-term survival imply an ever
greater beneﬁt of centralisation for the number
of patient-years than already presumed based
on short-term mortality, since the mortality
followed by such surgery is strongly dominated
by deaths from tumour recurrence rather than
procedure-related complications.
Brusselaers N, et al. Gut 2013;0:1–8. doi:10.1136/gutjnl-2013-306074 1
Oesophagus
 Gut Online First, published on November 22, 2013 as 10.1136/gutjnl-2013-306074
Copyright Article author (or their emp oyer) 2013. Produced by BMJ Publishing Group Ltd (& BSG) under licence. 
 group.bmj.com on November 24, 2013 - Published by gut.bmj.comDownloaded from 
account in previous research, which is of major concern when-
ever long-term mortality is the outcome. Thus, the impact of
surgery volume on long-term survival after oesophageal cancer
remains to be established. Such knowledge would be of clinical
importance since tumour recurrence in oesophageal cancer is
common, resulting in a risk of death of about 60–70% within
5 years of surgery.8 9 The objective of this study was to clarify
the association between hospital volume, surgeon volume and
hospital type in relation to long-term survival after oesophagect-
omy for cancer, by means of a meta-analysis.
METHODS
This was a systematic review and meta-analysis analysing differ-
ences in long-term survival between high-volume and low-
volume hospitals and surgeons after oesophagectomy for cancer.
The available literature was identiﬁed and examined by a sys-
tematic review and survival meta-analysis. The results are
reported in accordance with the PRISMA guidelines (Preferred
Reporting Items for Systematic Reviews and Meta-Analyses).10
The study followed an a priori established study protocol.
Exposure and outcome
The main exposure was surgery performed in either low- or
high-volume hospitals, as deﬁned by the authors of the included
studies. Other examined exposures were surgeon volume (low
or high) and type of hospital (eg, university or non-university).
Both surgeon and hospital volume were measured as the average
annual number of oesophagectomies per year (eg, >10 or <10
procedures/year). The group with the lowest volume or non-
university was used as reference category. If an included study
reported HRs for different surgical volume groups, only the
lowest and highest volume group were compared and reported
in the Forest plots.
The study outcome was the time to death after the oesopha-
gectomy, deﬁned by a minimal period of follow-up of the study
cohort of 3 months.
Data sources and searches
The primary data sources screened were PubMed and the Web
of Science. The search string in these databases consisted of four
parts: (1) the anatomical location of interest (ie, oesophagus,
oesophagectomy, and oesophageal), (2) surgery, surgical or
cancer, (3) outcome, mortality, survival or prognosis and (4)
volume, determinants or predictors. Different spelling was
accounted for, and medical subheadings (MeSH) were incorpo-
rated in the PubMed search. Complementary searches were
performed through analyses of reference lists, the Science
Citation index, Cochrane library, EMBASE and searching for
relevant publications of ‘expert’ authors (known or identiﬁed to
have published in the ﬁeld of surgery volume).
Study selection
The time period for publications was limited to January 1990–
September 2013, a period which we considered to represent
modern oesophageal cancer management. The search method
used to identify all relevant articles was discussed and developed
by two authors (NB and JL) and the ﬁnal search string was
approved by all authors. The initial search was performed by
one reviewer (NB), who eliminated clearly irrelevant articles
based on the title and abstract as deﬁned by the pre-set selection
criteria. The ﬁnal selection of articles was made by mutual con-
sideration of all authors, based on the reporting of all necessary
data and in accordance with the predeﬁned inclusion and exclu-
sion criteria.
Inclusion and exclusion criteria
Studies that provided original data on survival of patients who
underwent oesophagectomy for malignancy were included.
Abstracts or other conference proceedings, case reports, case
series, intervention studies and review articles were excluded.
Both prospective and retrospective studies were eligible. Articles
describing oesophagectomy for non-malignant reasons were
excluded, as were studies reporting a subgroup of oesophagect-
omy patients only. If studies also reported survival after gastric
cancer surgery, survival for oesophageal cancer had to be
reported separately, otherwise the study was excluded. Language
restriction was applied only in the end stage of the search, to
enable assessment of language selection bias. The languages
selected a priori as eligible were English, French, Dutch,
German, Spanish, Swedish and Chinese. Studies were eligible
only if HRs comparing survival after oesophagectomy by hos-
pital or surgeon volume groups, or by hospital type were
reported. The minimum reported follow-up time was 3 months.
Data extraction and quality assessment
The following data were collected (if available): study and popu-
lation characteristics, type of surgery and hospital characteristics.
Assessment of quality and generalisability was based on the key
domains considered fundamental for observational studies.11
From each article, the crude HRs were extracted (if reported),
and the HRs based on the most fully adjusted regression models
for the longest duration of follow-up. If several volume groups
were reported, the most extreme comparison —that is, highest
versus lowest reported volume, was considered the primary
result. If possible, the HR for hospital volume adjusted for
surgeon volume was extracted as well as the most fully adjusted
model without adjustment for surgeon volume. The same
approach was taken for surgeon volume and adjustment for hos-
pital volume. If HRs were reported including and excluding
‘early’ mortality, deﬁned as within 3 months of surgery, both
HRs were extracted, but the HR including the full follow-up
period was considered the main result.
Data synthesis and analysis
This survival meta-analysis pooled the HRs based on hospital
volume, surgeon volume and hospital type. Subanalysis was
based on duration of follow-up, inclusion or exclusion of early
mortality and reported regression models. Random-effect
meta-analyses were performed with STATA (StataCorp, V.12·1/
MP4), and were based on the HRs and SEs. The values were
reported by a Forest plot, and uncertainty about the pooled esti-
mates was quantiﬁed by 95% CI. If no SE was reported, it was
calculated based on the 95% CI, number of patients or reported
p values.12 13 The presence of small study effects and publica-
tion bias was evaluated by funnel plots and Egge’s regression
asymmetry analysis.14 Statistical heterogeneity was assessed by
means of Cochran’s Q test and I2 test. I2 represents the percent-
age of variation attributable to heterogeneity, which is usually
categorised as low (25–50%), moderate (51–75%) or high
(>75%).15
RESULTS
Description of the included studies
The search was ﬁnalised on 10 September 2013, and included a total
of 2392 publications as shown in the online supplementary appendix.
The search resulted in 16 eligible studies. Only one potentially eligible
Japanese study was excluded because of the language restriction.16
The eligible studies were from the USA (N=4),1 17–19 Sweden
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Table 1 Study and population characteristics of all 16 included studies dealing with survival after oesophageal cancer surgery
Author Year Region Cohort
Study
inclusion
period
Study
duration,
years
Age,
years
Male,
%
Adeno-
carcinoma, %
Squamous cell
carcinoma, % Exposure Mortality
Survival
after
Maximum
follow-up
time, years
Hospitals,
N
Oesophagectomies,
annual maximum
per hospital
Surgeons,
N
Oesophagectomies,
annual maximal
per surgeon
Coupland28 2013 England Population-based 2004–2008 5 nr 72* – – HV All cause Surgery >1 144 132 nr nr
Derogar20 2013 Sweden Population-based 1987–2005 15 Median
66
74 36 60 SV, HV All cause Surgery 23 nr ≥17 nr ≥10
Dikken (1)24 2012 Netherlands Population-based 1989–2009 21 nr 76 75 23 HV All cause Diagnosis 3 44 >20 nr nr
Dikken (2)25 2012 Netherlands Population-based 1989–2009 21 nr 76 75 23 HT All cause Diagnosis 3 44 >20 nr nr
van de
Poll-Franse26
2011 South Netherlands Population-based 1995–2006 12 Median
66
73–75 66–71 22–29 HV All cause Diagnosis 3 >12 15–20 nr 15–20
Cheung19 2010 Florida, USA Population-based 1998–2002 5 Median
69†
75† 48† 45† HT All cause nr 12? nr nr nr nr
Stavrou29 2010 New
S-Wales, Australia
Population-based 2000–2005 6 nr 74 nr nr HV From
cancer
Diagnosis 3 nr >20 nr nr
Bilimoria1 2008 USA Population-based 1994–1999 6 Median
64–65
nr nr nr HV All cause Surgery 5 1154 >15 nr nr
Sundelof22 2008 Sweden Population-based 1994–1997 4 nr 83 nr nr SV, HV All cause Surgery 5 33 ≥10 nr ≥10
Birkmeyer17 2007 USA Hospital/
NCI-centre based
1992–2002 11 nr 74–79 nr nr HV All cause Surgery 5 206 107 nr nr
Ioka31 2007 Osaka, Japan Population-based 1994–1998 5 nr nr nr nr HV All cause Diagnosis 5 143 >43 nr nr
Rouvelas21 2007 Sweden Population-based 1987–2000 14 Mean
65–66
71–72 26–29 59–66 HV All cause Surgery 5 22–30 ≥10 nr nr
Simunovic30 2006 Ontario, Canada Population-based 1990–2000 11 Median
63–65
nr nr nr HV, HT All cause Admission
for surgery
10? 68 ≥44 nr nr
Birkmeyer18 2005 USA Hospital/
NCI-centre based
1994–1999 6 nr 75–77 nr nr HT All cause Surgery 5 102 107 nr nr
Wenner23 2005 Sweden Population-based 1987–1996 10 Median
66–67†
75–
77†
77† 23† HV All cause Surgery 5 74 >20 nr 34
Bachmann27 2002 South and West
England
Hospital-based 1996–1997 1 nr nr nr nr SV, HV All cause Surgery 3 23 83 nr nr
*Also including patients with gastric carcinoma.
†Also including non-operated patients.
HT, hospital type; HV, hospital volume; nr, not reported; SV, surgeon volume .
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(N=4),20–23 the Netherlands (N=3),24–26 the UK (N=2),27 28
Australia (N=1),29 Canada (N=1)30 and Japan (N=1).31 The longest
reported follow-up was 23 years.20 Thirteen studies reported HRs
for survival by hospital volume groups (n=39 761),1 17 20–24 26–31
four by surgeon volume (n=2874),20 22 26 27 and four by hospital
type (n=13 433).18 19 25 26 Two of the three Dutch studies described
the same nationwide cohort, once for hospital volume and once for
hospital type,24 25 and there was some overlap with the third
(regional) study.26 The studies from the UK did not overlap.27 28
Some overlap was possible in the four American studies.1 17–19 The
study periods of the three oldest (nationwide) Swedish studies partly
overlapped.21–23 An overview of the main study characteristics is pre-
sented in table 1, and a quality assessment is shown in ﬁgure 1. All
but three studies 17 18 27 were population-based, and 10 studies were
nationwide. Eight studies also described other cancer types. Mean or
median age of patients undergoing the operation ranged from 63 to
66 years, as reported in four studies.1 20 21 30 The proportion of male
patients, as reported in nine studies, ranged from 71% to 83%. Four
studies reported the proportion of the main histological types: adeno-
carcinoma (26–75%) and squamous cell carcinoma (22–66%).20 21
24 25
Hospital volume and long-term survival
All 13 studies dealing with hospital volume reported adjusted
HRs. One study considered hospital volume as a continuous vari-
able (HR for an increase of 10 oesophagectomies per year) and
reported only HRs adjusted for surgeon volume.27 Another study
reported HRs both including and excluding adjustment for
surgeon volume.20 Ten studies reported HRs for the complete sur-
vival period, two of which also reported HRs excluding mortality
within the ﬁrst 2 months of surgery,1 or as ‘survived surgery’ (not
speciﬁed).17 Three studies reported only HRs excluding early mor-
tality— that is, the ﬁrst 2,23 3,20 or 624 postoperative months.20
Six studies adjusted for tumour stage.1 17 20 22 24 31
The pooled adjusted HRs of mortality in 12 studies (exclud-
ing the study adjusting for surgeon volume)27 was 0.82 (95% CI
0.75 to 0.90) in favour of high-volume hospitals (ﬁgure 2). The
statistical heterogeneity was moderate (I2=68.0%). Subanalyses
are presented in table 2, showing a pooled HR of 0.76 (95% CI
0.68 to 0.84) in studies adjusting for tumour stage. The seven
studies with the longest complete follow-up (over 3 years)
showed an HR of 0.77 (95% CI 0.69 to 0.87), and a survival
beneﬁt remained after exclusion of early mortality (HR=0.85,
95% CI 0.75 to 0.95) (table 2). In the two studies reporting
complete follow-up, and follow-up without early mortality,1 17
the HRs were 0.75 (95% CI 0.69 to 0.81) and 0.78 (95% CI
0.71 to 0.85), respectively, and I2=0%. In the two studies that
adjusted for surgeon volume, the HR was 1.01 (95% CI 0.97 to
1.06, I2=0%) (ﬁgure 2).
There was no evidence of publication bias or small-study
effects bias (p=0.313) (funnel plot not shown).
Surgeon-volume and long-term survival
The four studies that reported HRs for surgeon volume also
reported hospital volume.20 22 26 27 In one study, surgeon and
hospital volume were equivalent since all oesophagectomies
were performed by one surgical team led by one surgeon at
each specialised regional centre.26 One study reported the HR
for surgeon volume adjusted for hospital volume as a continu-
ous variable.27 Another study reported HRs with and without
adjustment for hospital volume.20 One study reported both hos-
pital and surgeon volume, but did not conduct any mutual
adjustment for these variables.22 Only one study excluded early
mortality (within 3 months of surgery).20 The follow-up time
ranged from 2 to 23 years.20 22 26 27 Only two studies adjusted
for tumour stage.20 22
As presented in ﬁgure 3, the pooled adjusted HR for surgeon
volume was 0.87 (95% CI 0.74 to 1.02) in favour of high
surgeon volumes. After further adjustment for hospital volume,
the pooled HR was 0.91 (95% CI 0.85 to 0.98). Statistical het-
erogeneity in both analyses was low (I2=0%).
There was no evidence of publication bias or small-study
effects bias (p=0.150) (funnel plot not shown).
Hospital type and long-term survival
Four studies analysed hospital type in relation to survival after
oesophagectomy.18 19 25 26 It was not possible to calculate a
pooled HR because of clinical heterogeneity between these
studies (ﬁgure 4).
Figure 1 Characteristics and quality assessment of all 16 included studies dealing with survival after oesophageal cancer surgery.
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DISCUSSION
This meta-analysis indicates a survival beneﬁt in favour of high-
volume hospitals and high-volume surgeons compared with the
low-volume equivalents. No independent risk reduction
remained for high hospital volume after adjustment for surgeon
volume, while high surgeon volume remained beneﬁcial after
adjustment for hospital volume.
Strengths of meta-analyses include the fact that they facilitate
objective evaluation and pooling of different study populations,
enable analyses of large and diverse cohorts of patients and
summarise the available evidence up to a certain time. Inherent
limitations of meta-analyses are that the results depend on the
availability, quality and methods of the published studies, and
they might be hampered by publication bias and clinical and
statistical heterogeneity. However, there was no evidence of pub-
lication bias in this study, and the statistical heterogeneity was
low to moderate. Language bias cannot be ruled out completely
since we based our search on English-language dominated
sources. Only one potentially eligible study was excluded
because of the language,16 but this Japanese study was con-
ducted by the same group as in an included study.31 Moreover,
even after implementing strict inclusion criteria, a considerable
clinical heterogeneity remained between study populations.
Moreover, meta-analyses assessing long-term survival are more
complex than those evaluating short-term mortality, because of
the need to take duration of survival and variation in follow-up
time into account.
Despite the heterogeneity between studies, this study provides
evidence of improved long-term survival when the oesophagect-
omy is conducted at high-volume hospitals and by high-volume
surgeons. This distinction between early mortality and long-
term mortality enables comparison of the underlying mechan-
isms; when patients die early after surgery it is usually owing to
complications, while later deaths are typically related to cancer
recurrence. This study showed that even after excluding the ﬁrst
months after surgery, a 15% beneﬁt in favour of high-volume
hospitals remained, indicating that surgery volume inﬂuences
the risk of tumour recurrence. These ﬁndings support centralisa-
tion of oesophageal cancer surgery to fewer surgeons working
at centres of excellence in this ﬁeld.32–34 The discussion about
which hospital and surgeon volume should be recommended
cannot be answered by this study. As in other meta-analyses 2 6
Figure 2 Forrest plot of survival beneﬁt based on annual hospital volume of oesophageal cancer surgery, in 13 studies. The adjusted HRs are
based on the most fully adjusted models as reported for each study, excluding or including adjustment for surgeon volume. ¤Hospital volume was
reported as average per quartile (range per quartile not reported). *Hospital volume was considered a continuous variable and HRs were reported
for an increase of 10 units.
Table 2 Subanalyses for survival by hospital volume of the 12
studies reporting HRs without adjustment for surgeon volume of
oesophageal cancer surgery
Hospital volume (N=12) HR 95% CI N studies I2
All 0.82 0.75 to 0.90 12 68.0
Adjusted for tumour stage 0.76 0.68 to 0.84 6 67.0
Not adjusted for tumour stage 0.91 0.83 to 1.00 6 11.8
Early mortality excluded 0.85 0.75 to 0.95 5 68.3
Complete follow-up* 0.78 0.70 to 0.87 9 61.4
Long follow-up (>3 years) 0.80 0.71 to 0.89 8 70.1
Long and complete follow-up (>3 years)* 0.77 0.69 to 0.87 7 67.1
Short follow-up (max 3 years) 0.90 0.72 to 1.14 4 71.4
Short and complete follow-up
(max 3 years)*
0.97 0.55 to 1.73 2 50.1
*Complete follow-up includes only studies reporting survival including mortality
within the early postoperative period.
Values are presented as pooled HRs and 95% CIs, with low-volume hospital groups
as reference category. The I2 represents the percentage of variation attributable to
heterogeneity, categorised as low (25–50%), moderate (51–75%) or high (>75%).
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we compared the largest volume group with the lowest volume
group when different thresholds were used, so based on this
study design we cannot deﬁne a recommended quantity of
annual oesophagectomies by hospital or surgeon.
The ﬁndings of this study complement previous meta-analyses
evaluating short-term mortality after oesophagectomy, with
pooled ORs of 0.20–0.40 for high-volume hospitals compared
with low-volume hospitals.2 4 6 35 However, deaths from
tumour recurrence after oesophageal cancer surgery are far
more common (60–70%) than deaths occurring during the
initial postoperative period (<5%), emphasising the relevance
of evaluating surgery volume in relation to longer-term survival.
Yet, this issue has been dealt with in only a few systematic
reviews,4 6 36–38 and one meta-analysis based on four studies.6
The previous meta-analysis showed an OR of survival of 1.17
(95% CI 1.05 to 1.31) in favour of high-volume hospitals, but it
did not take the time to death into account.6 Nevertheless, the
ﬁnding of that meta-analysis is in line with the results of our
study.
An important, yet complex, question is the underlying mech-
anism of the ﬁndings of this study, and if hospital and surgeon
volumes should be considered separate entities or merely
proxies of each other. The surgery volume effect might be due
to the total package of multidisciplinary teams, advanced
Figure 3 Forrest plot of survival beneﬁt based on annual surgeon volume of oesophageal cancer surgery, based on four studies. The adjusted HRs
are based on the most fully adjusted models as reported for each study, excluding or including adjustment for hospital volume. *Surgeon volume
was considered a continuous variable and HRs were reported for an increase of 10 units.
Figure 4 Forrest plot of survival beneﬁt of hospital type of oesophageal cancer surgery, based on four studies. The adjusted HRs are based on the
most fully adjusted models as reported for each study. AdenoCa, adenocarcinoma; NCI, National Cancer Institute (USA); SCC, squamous cell
carcinoma. University and teaching hospitals were assumed to have a higher volume than non-university and non-teaching hospitals; NCI hospitals
had similar hospital volumes to the control hospitals.
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diagnostics, treatment and care, or alternatively, it might mainly
be due to the experience and expertise of the surgeon and the
surgical team. This study found no association between hospital
volume and survival when considering only the two studies
adjusting for surgeon volume, but interestingly, the inﬂuence of
surgeon volume remained after adjusting for hospital volume.
Although based on a small number of studies, this might suggest
a more important role for surgeon volume than hospital
volume.
It is important to point out that survival depends not only on
surgery volume.39 Substantial logistical and case-mix differences
exist between countries, especially for geographical distances
and tumour incidence. A related question is if the patient popu-
lation and case-mix, particularly for tumour stage and socio-
economic status, are similar between volume groups.40 41 In an
attempt to adjust for such confounding, we included only the
most fully adjusted regression models. The six studies including
adjustment for tumour stage, the strongest prognostic factor,
showed a larger effect than those which did not adjust (24% vs
9%), which indicates robustness of the ﬁndings of this study.
The size of the effect of high surgery volume in relation to
long-term survival after oesophageal cancer surgery is not negli-
gible. The effect size is similar to the effect of preoperative
oncological therapy that has been demonstrated in recent large
meta-analyses,42 and neoadjuvant therapy has therefore become
routine clinical practice for these patients in most countries. It
therefore seems logical that centralisation of this surgery should
be a prioritised measure to improve the prognosis in oesopha-
geal cancer.
To conclude, this meta-analysis of long-term survival after
oesophageal cancer surgery showed an 18–25% and 9–13%
improved survival for high-volume hospitals and high-volume
surgeons, respectively, compared with their low-volume counter-
parts. This difference in survival was not solely due to a
decreased early postoperative mortality, since even after exclu-
sion of early deaths, a 15% beneﬁt was found. Surgeon volume
appears to be more strongly related to survival than hospital
volume.
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